Documents

Imaging-driven growth funds late-stage trials in urology and neuro-oncology, with major data ahead.

FDA approval, pipeline expansion, and integrated distribution drive radiopharma leadership.

Revenue up 22% to $477M, with robust growth, pipeline progress, and guidance at upper end.

Q2 2026 revenue up 21% YoY to US $247M, with FY 2026 revenue expected to surpass US $1B.

TLX101 and Pixclara advance neuro-oncology with promising survival, safety, and diagnostic gains.

Theranostics pipeline, PSMA growth, and new clinical assets drive future expansion.

Strong commercial growth and late-stage oncology pipeline drive global expansion and innovation.

Record revenue, global board renewal, and pipeline progress set stage for future growth.

TLX597-Tx enables safer, more targeted prostate cancer therapy with adaptive dosing potential.

Q1 2026 revenue rose 11% sequentially, with strong Precision Medicine growth and guidance reaffirmed.

2026 revenue guidance raised to $950–$970 million, with robust pipeline and market expansion.

TLX591 plus standard care showed strong safety and dosimetry, enabling global Phase III expansion.

PSMA PET/CT advances and robust supply chains are driving efficient, high-impact prostate cancer care.

Late-stage therapeutics, new launches, and global expansion drive strong 2026 growth outlook.

Advancing global radiopharmaceutical leadership with major clinical and commercial milestones ahead.

56% revenue growth and strong guidance, with major R&D reinvestment and new launches ahead.